Experts say we’re in a golden age for treating chronic kidney disease, with new drugs like Ozempic yielding major results.

Within the guidelines it is mentioned that treatment with Filspari, may be an appropriate first-line approach to manage the responses of IgAN-induced nephron loss in contrast to the RASi-first ...